Abstract
Advances in multiple myeloma (MM) treatment, including novel agents and autologous stem cell transplant, have led to improved outcomes in survival. However, these treatment regimens are time intensive, complex and length of treatment is indefinite. Supportive care for complications including bone disease, hypercalcemia and anemia is frequently needed. Given this treatment burden, access to care may be influential in survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
